neurology articles
This copy is for your personal, non-commercial use only. Monday morning, Sage reported top-line results from a Phase 2 study on one of those drugs, for patients suffering from essential tremor.
The overall market was only fractionally lower. Sage tested its SAGE investigational drug against a placebo among 67 patients with the shake-inducing neurological disorder, which affects neurology articles many as 6 million Americans. These results were just borderline significant by statistical standards, however, with the probability of the difference being a lucky accident at 0. He noted that patients on the drug also reported improved ease in their daily activities.
Publications
The drug neurology articles side effects, however. On a Monday conference call, the Sage executives said that they had deliberately started on a high dose, to test for an effect, and can try other doses in another planned Phase 2 study. In a note, Raymond James analyst Danielle Brill said here data left her with more questions than answers about the drug.
Studies at lower doses will need to be done.
There is none, he said, because prospects https://digitales.com.au/blog/wp-content/custom/negative-impacts-of-socialization-the-positive-effects/wiz-khalifa-building.php SAGE matter little in proportion to the June 7 deadline for an approval articoes by the U. Biogen stock is all about aducanumab, says Seedhouse. Write to Bill Alpert at william. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Neurology articles Jones Reprints at or visit www.
We've detected you are on Internet Explorer. For the best Barrons.
Filter News
Google Firefox. Text size. Thank you This article has been sent to. Privacy Notice. Cookie Notice. Copyright Policy. Data Policy. Your Ad Choices.
Barron's Archive. All Rights Reserved. All Rights Reserved This copy is for your personal, non-commercial use only.]
It — is improbable!